Pediatric erythroblastic transformation of JAK 2‐mutated prefibrotic primary myelofibrosis with concurrent PHF6 mutations
Pediatric Blood & Cancer · 2023
DOI: 10.1002/pbc.30508 ↗At a glance
Fallbericht in Pediatric Blood & Cancer, 2023. Written by Tokiko Oshiro and 7 co-authors. Institution: Department of Pediatrics, University of Ryukyus Hospital, Nakagami-gun, Japan. Major MEDLINE topics: Primary Myelofibrosis. 11 references.
Abstract (original language)
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Department of Pediatrics, University of Ryukyus Hospital, Nakagami-gun, Japan.
- Okinawa Prefectural Red Cross Blood Center, Naha, Japan.
- Department of Pathology and Oncology, Graduate School of Medicine, University of Ryukyus, Nakagami-gun, Japan.
- Department of Pediatrics, Graduate School of Medicine, University of Nagoya, Nagoya, Japan.
- Department of Pediatrics, Graduate School of Medicine, University of The Ryukyus, Nakagami-gun, Japan.
ORCID profiles: Satoru Hamada
Cite
APA
Oshiro, T., Hamada, S., Kiyuna, S., Sakiyama, H., Hyakuna, N., Tamaki, T., Muramatsu, H., & Nakanishi, K. (2023). Pediatric erythroblastic transformation of JAK 2‐mutated prefibrotic primary myelofibrosis with concurrent PHF6 mutations. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.30508
Vancouver
Oshiro T, Hamada S, Kiyuna S, Sakiyama H, Hyakuna N, Tamaki T, et al. Pediatric erythroblastic transformation of JAK 2‐mutated prefibrotic primary myelofibrosis with concurrent PHF6 mutations. Pediatric Blood & Cancer. 2023. doi:10.1002/pbc.30508
BibTeX
@article{Oshiro2023,
author = {Oshiro, Tokiko and Hamada, Satoru and Kiyuna, Sinobu and Sakiyama, Hideki and Hyakuna, Nobuyuki and Tamaki, Tomoko and Muramatsu, Hideki and Nakanishi, Koichi},
title = {Pediatric erythroblastic transformation of JAK 2‐mutated prefibrotic primary myelofibrosis with concurrent PHF6 mutations},
journal = {Pediatric Blood & Cancer},
year = {2023},
doi = {10.1002/pbc.30508}
}
EUVIMED